We stratified our cohort of CRC patients into four groups according to the combination of different HDGF and β-catenin expression levels: group 1, low HDGF/normal β-catenin expression; group 2, low HDGF/abnormal β-catenin expression; Group 3, high HDGF/normal β-catenin expression and; and group 4, high HDGF/abnormal β-catenin expression. This evidence concerns the gene HDGF and colorectal carcinoma.